Marina Starts Dosing in Familial Adenomatous Polyposis Drug Trial

The study will consist of 12 patients in four dose-escalating cohorts.

Marina Biotech has initiated patient dosing in a Phase Ib/IIa trial evaluating CEQ508 in patients with familial adenomatous polyposis. The study will evaluate the safety and tolerability of CEQ508 after 28 days of daily oral dosing.

Familial adenomatous polyposis is a hereditary condition characterised by the formation of numerous polyps throughout the large intestine, which can lead to bleeding, anaemia, abdominal pain, diarrhoea, and constipation.

The study will consist of 12 patients in four dose-escalating cohorts.

The trial is also intended to provide data on beta-catenin biomarker changes pre- and post-treatment, as wel